General Information of Drug (ID: DMV7T64)

Drug Name
Talactoferrin Drug Info
Synonyms Talactoferrin (topical)
Indication
Disease Entry ICD 11 Status REF
Diabetic foot ulcer BD54 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMV7T64

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Lactotransferrin (LTF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Parecoxib DMIV8CT N. A. N. A. Phase 4 [3]
HLF 1-11 DMDFG1O Bacteremia 1A73 Phase 1/2 [4]
Nimesulide DMR1NMD Metastatic colorectal cancer 2B91 Terminated [5]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [6]
Fucose DMAHMSV N. A. N. A. Investigative [6]
Lauric Acid DM9C8KQ Discovery agent N.A. Investigative [6]
Alpha-D-Fucose DM6VH7A Discovery agent N.A. Investigative [6]
Nitrilotriacetic Acid DMIOQFU Discovery agent N.A. Investigative [6]
3h-Indole-5,6-Diol DMBFCTZ Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lactotransferrin (LTF) TTSZDQU TRFL_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00706862) Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer. U.S. National Institutes of Health.
2 Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54.
3 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
4 The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21.
5 Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.